Patent · US Active

Haloallylamine dual amine oxidase inhibitors

US12428370B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

Syntara Limited · AU

Inventors

Alan D. Robertson · Hornsby, AU
Alison Dorothy Findlay · Chatswood, AU
Alberto Buson · Chatswood, AU
Craig Ivan Turner · Forbes, AU
Dieter Hamprecht · Verona, IT
Jonathan Stuart Foot · Chatswood, AU
Mandar Deodhar · Chatswood, AU
Wolfgang Jarolimek · Chatswood, AU
Serena Becchi · Fawn Drive, AU
Bernard Walter Balleine · Sydney, AU
Marcella Canton · Isola di Terranegra, IT
Libero Vitiello · Isola di Terranegra, IT
Bert Blaauw · Isola di Terranegra, IT

Key dates

Filing date	Jun 25, 2021
Grant date	Sep 30, 2025
Priority date	—
Expiry date	Aug 26, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.